Influenza M2 protein mutant viruses as live influenza attenuated vaccines
AssigneeWisconsin Alumni Research Foundation
InventorsTokiko Watanabe, Yoshihiro Kawaoka
Life of this patent
Estimating the term…
Abstract
A method to prepare recombinant influenza viruses comprising a mutant M2 protein which has a deletion of two or more residues in the cytoplasmic tail and is attenuated in vivo, is provided, as well the resulting virus and vaccines with the virus.
Claims38
An immunogenic composition comprising an isolated, live, in vivo attenuated recombinant influenza virus comprising a PA viral gene segment, a PB1 viral gene segment, a PB2 viral gene segment, a HA viral gene segment, a NA viral gene segment, a NP viral gene segment, a M viral gene segment having coding sequences for M1 and M2, and a NS viral gene segment having coding sequences for NS I and NS2, wherein the M gene segment comprises a mutant M2 protein gene for a M2 protein which has a deletion consisting of 9 to 15 residues of the C-terminus of the cytoplasmic tail which M2 protein is encoded by the mutant M2 protein gene, wherein the deletion attenuates the replication of the recombinant virus in vivo relative to the corresponding influenza virus without the deletion, wherein the composition comprises at least 0.1 micrograms to 200 micrograms influenza virus hemagglutinin (HA).
An immunogenic composition comprising a live, in vivo attenuated influenza virus with a M gene segment comprising a mutant M2 protein gene, wherein the mutant M2 protein gene has a mutation that codes for a deletion of 1 to 22 residues from the C-terminus of the M2 protein and a HA gene segment for a H5 HA with an HA cleavage site of an avirulent influenza virus, wherein the composition comprises 0.1 to 200 micrograms of influenza virus hemagglutinin (HA).
Dependencies are inferred from the claim text.